These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8243674)

  • 21. Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin.
    Ni H; Blajchman MA; Ananthanarayanan VS; Smith IJ; Sheffield WP
    Thromb Res; 2000 Aug; 99(4):407-15. PubMed ID: 10963791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin.
    Huntington JA; Gettins PG
    Biochemistry; 1998 Mar; 37(10):3272-7. PubMed ID: 9521646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular and functional characterization of three recombinant antithrombin mutants that caused pleiotropic effect-type deficiency.
    Shirotani H; Tokunaga F; Koide T
    J Biochem; 1999 Feb; 125(2):253-62. PubMed ID: 9990121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Importance of the P2 glycine of antithrombin in target proteinase specificity, heparin activation, and the efficiency of proteinase trapping as revealed by a P2 Gly --> Pro mutation.
    Chuang YJ; Gettins PG; Olson ST
    J Biol Chem; 1999 Oct; 274(40):28142-9. PubMed ID: 10497166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Critical role of the linker region between helix D and strand 2A in heparin activation of antithrombin.
    Meagher JL; Olson ST; Gettins PG
    J Biol Chem; 2000 Jan; 275(4):2698-704. PubMed ID: 10644732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the C-sheet in the maturation of N-glycans on antithrombin: functional relevance of pleiotropic mutations.
    Aguila S; Navarro-Fernández J; Bohdan N; Gutiérrez-Gallego R; de la Morena-Barrio ME; Vicente V; Corral J; Martínez-Martínez I
    J Thromb Haemost; 2014 Jul; 12(7):1131-40. PubMed ID: 24824609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of Arg46 and Arg47 of antithrombin in heparin binding.
    Arocas V; Bock SC; Olson ST; Björk I
    Biochemistry; 1999 Aug; 38(31):10196-204. PubMed ID: 10433728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation of the H-helix in antithrombin decreases heparin stimulation of protease inhibition.
    Gonzales PR; Walston TD; Camacho LO; Kielar DM; Church FC; Rezaie AR; Cooper ST
    Biochim Biophys Acta; 2007 Nov; 1774(11):1431-7. PubMed ID: 17905675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific roles for the asparagine-linked carbohydrate residues of recombinant human follicle stimulating hormone in receptor binding and signal transduction.
    Bishop LA; Robertson DM; Cahir N; Schofield PR
    Mol Endocrinol; 1994 Jun; 8(6):722-31. PubMed ID: 7935488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding.
    Arocas V; Bock SC; Raja S; Olson ST; Bjork I
    J Biol Chem; 2001 Nov; 276(47):43809-17. PubMed ID: 11567021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombin Rouen-IV 24 Arg----Cys. The amino-terminal contribution to heparin binding.
    Borg JY; Brennan SO; Carrell RW; George P; Perry DJ; Shaw J
    FEBS Lett; 1990 Jun; 266(1-2):163-6. PubMed ID: 2365065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site.
    Petitou M; Casu B; Lindahl U
    Biochimie; 2003; 85(1-2):83-9. PubMed ID: 12765778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation.
    Beauchamp NJ; Pike RN; Daly M; Butler L; Makris M; Dafforn TR; Zhou A; Fitton HL; Preston FE; Peake IR; Carrell RW
    Blood; 1998 Oct; 92(8):2696-706. PubMed ID: 9763552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Partial activation of antithrombin without heparin through deletion of a unique sequence on the reactive site loop of the serpin.
    Rezaie AR
    J Biol Chem; 2002 Jan; 277(2):1235-9. PubMed ID: 11707451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.
    Borg JY; Owen MC; Soria C; Soria J; Caen J; Carrell RW
    J Clin Invest; 1988 Apr; 81(4):1292-6. PubMed ID: 3350974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
    Lin P; Sinha U; Betz A
    Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serine 380 (P14) --> glutamate mutation activates antithrombin as an inhibitor of factor Xa.
    Futamura A; Gettins PG
    J Biol Chem; 2000 Feb; 275(6):4092-8. PubMed ID: 10660568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antithrombin and its deficiency states.
    Lane DA; Olds RR; Thein SL
    Blood Coagul Fibrinolysis; 1992 Jun; 3(3):315-41. PubMed ID: 1643210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding.
    Peterson CB; Blackburn MN
    J Biol Chem; 1985 Jan; 260(1):610-5. PubMed ID: 3965464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antithrombin and heparin.
    Carrell R; Skinner R; Warden M; Whisstock J
    Mol Med Today; 1995 Aug; 1(5):226-31. PubMed ID: 17607884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.